• Explore /
  • Poster
  • / Genomic and immune landscape of metastatic melanoma (MM) treated with pembrolizumab (PEM).

Genomic and immune landscape of metastatic melanoma (MM) treated with pembrolizumab (PEM).

Abstract Poster

Authors

Yada Kanjanapan

Yada Kanjanapan

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Yada Kanjanapan, Scott Lien, Cindy Yang, Derek L. Clouthier, Sawako Elston, Haiyan Jiang, Marcus O. Butler, David Hogg, Pamela S Ohashi, Trevor John Pugh, Lillian L. Siu, Anna Spreafico

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies

Sub Track

Biomarkers and Inflammatory Signatures

Clinical Trial Registration Number

NCT02644369

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr 184)

DOI

10.1200/JCO.2018.36.5_suppl.184

Abstract #

184

Poster Bd #

J1

Abstract Disclosures

Similar Posters

First Author: Ilaria Colombo

First Author: Laura Cattaneo

First Author: Camila Bragança Xavier

First Author: Nicholas Coupe